DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
[Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicent...
| Autores: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2019 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/212324 |
| Acceso en línea: | http://hdl.handle.net/10261/212324 |
| Access Level: | acceso abierto |
| Palabra clave: | Endocarditis Bloodstream infections Dalbavancin |
| id |
ES_3471969302cd68e5eeefdbeb852548cd |
|---|---|
| oai_identifier_str |
oai:digital.csic.es:10261/212324 |
| network_acronym_str |
ES |
| network_name_str |
España |
| spelling |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci Hidalgo-Tenorio, Carmen Vinuesa García, David Plata-Ciezar, Antonio Martín-Dávila, Pilar Iftimie, Simona Sequera, Sergio Loeches, Belén López-Cortés, Luis Eduardo Fariñas, María del Carmen Fernández-Roldán, Concepción Javier-Martinez, Rosario Muñoz García, Patricia Arenas-Miras, Maria del Mar Martínez-Marcos, Francisco Javier Miró, José María Herrero-Rodríguez, Carmen Bereciartúa, Elena De Jesus, Samantha E. Pasquau-Liaño, Juan Endocarditis Bloodstream infections Dalbavancin [Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. [Results] Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). [Conclusions] DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug. BioMed Central http://hdl.handle.net/10261/212324 |
| title |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
| spellingShingle |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci Hidalgo-Tenorio, Carmen Endocarditis Bloodstream infections Dalbavancin |
| title_short |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
| title_full |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
| title_fullStr |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
| title_full_unstemmed |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
| title_sort |
DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
| author |
Hidalgo-Tenorio, Carmen |
| author_facet |
Hidalgo-Tenorio, Carmen Vinuesa García, David Plata-Ciezar, Antonio Martín-Dávila, Pilar Iftimie, Simona Sequera, Sergio Loeches, Belén López-Cortés, Luis Eduardo Fariñas, María del Carmen Fernández-Roldán, Concepción Javier-Martinez, Rosario Muñoz García, Patricia Arenas-Miras, Maria del Mar Martínez-Marcos, Francisco Javier Miró, José María Herrero-Rodríguez, Carmen Bereciartúa, Elena De Jesus, Samantha E. Pasquau-Liaño, Juan |
| author_role |
author |
| author2 |
Vinuesa García, David Plata-Ciezar, Antonio Martín-Dávila, Pilar Iftimie, Simona Sequera, Sergio Loeches, Belén López-Cortés, Luis Eduardo Fariñas, María del Carmen Fernández-Roldán, Concepción Javier-Martinez, Rosario Muñoz García, Patricia Arenas-Miras, Maria del Mar Martínez-Marcos, Francisco Javier Miró, José María Herrero-Rodríguez, Carmen Bereciartúa, Elena De Jesus, Samantha E. Pasquau-Liaño, Juan |
| author2_role |
author author author author author author author author author author author author author author author author author author |
| topic |
Endocarditis Bloodstream infections Dalbavancin |
| topic_facet |
Endocarditis Bloodstream infections Dalbavancin |
| description |
[Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. [Results] Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). [Conclusions] DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug. |
| publishDate |
2019 |
| format |
article |
| status_str |
publishedVersion |
| url |
http://hdl.handle.net/10261/212324 |
| eu_rights_str_mv |
openAccess |
| publisher |
BioMed Central |
| institution |
Consejo Superior de Investigaciones Científicas (CSIC) |
| collection |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| reponame_str |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| _version_ |
1878433251968679936 |
| publishDateSort |
2019 |
| author_browse |
Arenas-Miras, Maria del Mar Bereciartúa, Elena De Jesus, Samantha E. Fariñas, María del Carmen Fernández-Roldán, Concepción Herrero-Rodríguez, Carmen Hidalgo-Tenorio, Carmen Iftimie, Simona Javier-Martinez, Rosario Loeches, Belén López-Cortés, Luis Eduardo Martín-Dávila, Pilar Martínez-Marcos, Francisco Javier Miró, José María Muñoz García, Patricia Pasquau-Liaño, Juan Plata-Ciezar, Antonio Sequera, Sergio Vinuesa García, David |
| publisherStr |
BioMed Central |
| score |
6,924472 |